Apr 3 |
ReShape Lifesciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
Apr 1 |
ReShape Lifesciences reports FY results
|
Apr 1 |
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
|
Mar 28 |
ReShape Lifesciences gets notice of allowance for additional U.S. patent
|
Mar 28 |
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
|
Mar 4 |
ReShape Lifesciences sees 55.4% fall in Y/Y expenses in 2024 with cost cut plan
|
Mar 4 |
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
|
Feb 22 |
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
|
Jan 24 |
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
|
Dec 20 |
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
|